Alnylam Pharmaceuticals (ALNY) Key Value Driver Entering Phase 2 - Jefferies

July 1, 2021 9:16 AM EDT Send to a Friend
Jefferies analyst Maury Raycroft reiterated a Buy rating and $193.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) on the belief ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login